Hints and tips:
...Shahzad Malik General Partner, Advent Life Sciences Dr Angel Salazar Chief Executive, AIDA Technology David Sharples Chief Executive, AKL Research and Development Ian Harrison Director, Alchemy Pharmatech...
...US pharmaceutical research company Charles River Laboratories and China’s WuXi Pharmatech have agreed to terminate their $1.6bn deal that would have been the largest US takeover of a Chinese company, reports...
...Charles River Laboratories, the US drug research company, has called off a $1.6bn (€1.23bn, £1.02bn) deal to buy China’s WuXi PharmaTech after its largest shareholders voiced strong opposition and influential...
...If Charles River Laboratories had gone ahead with next week’s shareholder vote on its proposed acquisition of Wuxi PharmaTech – which could have been China’s biggest inbound takeover yet – it would have...
...Charles River Laboratories, the US drug research firm, has agreed to buy Chinese rival Wuxi PharmaTech for US$1.6bn, the FT reports....
...Charles River Laboratories International fell 2.7 per cent to $31.08 after it agreed to end its merger agreement with Wuxi PharmaTech, paying $30m to break the contract....
...Charles River Laboratories, the US drug research firm, has agreed to buy Wuxi PharmaTech, a Chinese rival, for US$1.6bn as western pharmaceutical companies increase outsourcing of their research and development...
...WuXi PharmaTech, a Chinese pharmaceutical group, added 17.1 per cent to $19.41 on news that Charles River Laboratories had agreed to buy the company for about $1.6bn in order to expand its global footprint...
...says P S Gopalakrishnan, director of IBM India Research Laboratory in Delhi. ?...
International Edition